Filing Flows › 13F managers › Johnson & Johnson
Johnson & Johnson: 13F portfolio Q3 2026 and what copying it returned
Johnson & Johnson's 13F for the quarter ended 2026-09-30 (filed Oct 26, 2026): 15 common-share positions, $762M reported. Copying each 13F the day after it was filed returned +172.3% from Jun 2, 2022 to Nov 6, 2026, against +79.5% for SPY.
Copying the 13F
Each 13F bought at the close of the first trading day after it was filed and held, drifting, until the next one; value-weighted over the common-share positions with a price (84.7% of the portfolio on average); 18 filings since Feb 14, 2022. Price returns for the clone and SPY alike (no dividends, no costs). A 13F lists only US long positions at quarter end, reported up to 45 days later.
Largest holdings (2026-09-30)
| Ticker | Company | Weight | Value | Change in the quarter |
|---|---|---|---|---|
| PTGX | Protagonist Therapeutics | 45.3% | $345M | unchanged |
| NBTX | Nanobiotix S.A. | 23.0% | $175M | unchanged |
| RAPP | Rapport Therapeutics | 7.9% | $60.0M | unchanged |
| CTNM | Contineum Therapeutics | 3.5% | $26.6M | unchanged |
| CBRS | Cerebras Systems | 3.0% | $22.9M | +140.1% |
| XNCR | Xencor | 2.5% | $18.7M | unchanged |
| LEGN | Legend Biotech | 2.1% | $16.2M | unchanged |
| FATE | Fate Therapeutics | 1.1% | $8.0M | unchanged |
| CVRX | CVRx | 0.9% | $7.0M | unchanged |
| PRCT | Procept BioRobotics | 0.9% | $6.5M | unchanged |
| NMRA | Neumora Therapeutics | 0.1% | $1.1M | unchanged |
| VOR | Vor Biopharma | 0.1% | $1.0M | unchanged |
| LAB | Standard Biotools | 0.0% | $231K | unchanged |
| ACET | Adicet Bio | 0.0% | $163K | unchanged |
Biggest adds
- CBRS +140.1%
Biggest cuts
- None reported.
Track record
Of 24 position changes scored in 24 separate decisions, 50.0% were on the right side of SPY over the next three months (Disclosures → Smart money).
Open in Disclosures → every quarter, the clone month by month, the smart-money record
Source: SEC Form 13F-HR, filer CIK 200406. Not investment advice.